![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
. | ![]() |
. |
![]() by Staff Writers Tokyo (AFP) March 18, 2020
Shares in Japanese firm Fujifilm Holdings sky-rocketed on Wednesday after Chinese authorities said a drug produced by the company could be effective for treating coronavirus patients. Fujifilm Holdings stock started the day untraded because of a glut of buy orders, before soaring 15.4 percent to 5,238 yen, the highest level allowed during trade for the day. China's ministry of science and technology said late Tuesday that some clinical trials have been completed on favipiravir -- the main ingredient in the influenza drug Avigan, which Fujifilm markets. The trials using the drug as a treatment for COVID-19 showed "very good clinical results", an official said at a press conference. A trial involving 80 cases conducted by a hospital in Shenzhen and a study of 120 cases led by Wuhan University's Zhongnan Hospital both showed the drug shortened the recovery time for patients. Better known for its cameras, Fujifilm developed Avigan and has licensed the patent for favipiravir to Chinese company Zhejiang Hisun Pharmaceutical. The Japanese firm told AFP it was not involved in the clinical tests in China, but "as for Avigan, we have received supply requests from several countries while the Japanese government has asked us to study if we will be able to step up production." "We are now examining obstacles to be cleared to boost production," a spokesman said. Fujifilm and the Chinese licence holder are in "a cooperative relationship" but the Japanese firm is not involved in production in China, he added. Clinical tests using Avigan as a treatment for the virus have also started in Japan. The coronavirus outbreak, which first emerged in China late last year, has quickly marched across the globe, infecting nearly 200,000 people and killing 7,900 as governments scramble to contain it. mis-kh/qan
![]() ![]() US Navy reports first suspected virus case on ship Washington (AFP) March 16, 2020 The US Navy reported its first suspected case of the new coronavirus aboard a ship, saying a sailor had tested positive for the disease but the result needed to be confirmed by health authorities. It came a week after another US Navy sailor stationed in southern Italy contracted COVID-19, which has killed more than 3,700 people worldwide including nearly 70 in the United States. "A Sailor assigned to the amphibious assault ship USS Boxer (LHD 4) tested 'presumptive positive' for Coronavirus Dise ... read more
![]() |
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |